Anti-PD-1 or anti-PD-L1 antibodies can block the interaction of PD-1 with PD-L1 and reverse the inhibition of CD8+ T cells, thereby enhancing anti-tumor activity (Figure 3). This evidence concerns the gene CD274 and neoplasm.